141 results
8-K
FOLD
Amicus Therapeutics Inc
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
to, “look forward to,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” "confidence," "encouraged," “potential,” “plan,” “targets,” “likely
8-K
EX-99.1
t2xlv0c5 na
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
8-K
EX-99.1
fif17 6jzd0
21 Aug 23
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
7:01am
8-K
EX-99.1
6ud81btmlm3
15 Aug 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
7:00am
8-K
EX-99.1
sj8h42
27 Jun 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
7:01am
8-K
EX-99.1
2acjnvdf7p f3djf83c
26 Apr 23
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
2:04pm
8-K
EX-99.1
uma20yl4tyxic9l7pem
16 Dec 22
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
8:17am
8-K
EX-99.1
u927v1z7b6
28 Oct 22
U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
5:18pm
8-K
EX-10.1
u0fqes 5z1
1 Aug 22
Departure of Directors or Certain Officers
5:10pm
8-K
EX-99.1
60gs m6iqf0euvqt
10 May 22
Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA
4:01pm
8-K
te28n 71u
24 Feb 22
Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates
7:00am
8-K
EX-10.2
6ko9uyy9cs558prjr3
24 Feb 22
Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates
7:00am